<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="452">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693520</url>
  </required_header>
  <id_info>
    <org_study_id>ALZ-801-201ADBM</org_study_id>
    <nct_id>NCT04693520</nct_id>
  </id_info>
  <brief_title>Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease</brief_title>
  <official_title>A Phase 2, Single-arm Study of the Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzheon Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alzheon Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effects of oral ALZ-801, in subjects with Early AD who have&#xD;
      the APOE4/4 or APOE3/4 genotype, on the biomarkers of core AD pathology. The objectives of&#xD;
      this study include determining the efficacy and safety/tolerability of ALZ-801. In addition,&#xD;
      the study will evaluate the extended PK profile over 8 hours in 16 subjects after 65 weeks of&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebrospinal Fluid (CSF) Biomarker of Core AD Pathology</measure>
    <time_frame>Week 104</time_frame>
    <description>Percent change from baseline in p-tau181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, Nature, and Severity of Treatment Emergent Adverse events (TEAE)</measure>
    <time_frame>Week 108</time_frame>
    <description>Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAE, and TEAE leading to withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional CSF Biomarkers of AD Pathology and Neurodegeneration</measure>
    <time_frame>Week 104</time_frame>
    <description>Percent changes from baseline for: p-tau217,Aβ-40, Aβ-42, NfL, t-tau, sTREM2, YKL-40 and neurogranin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Biomarkers of AD and Neurodegeneration</measure>
    <time_frame>Week 104</time_frame>
    <description>Percent changes from baseline in: p-tau181, NfL, Aβ-40, Aβ-42,p-tau217 and plasma glial fibrillary acidic protein (GFAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric Magnetic Resonance Imaging (vMRI) Biomarker - Hippocampal Volume</measure>
    <time_frame>Week 104</time_frame>
    <description>Change from baseline in hippocampal volume measured in mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vMRI Biomarker - Cortical Thickness</measure>
    <time_frame>Week 104</time_frame>
    <description>Change from baseline in cortical thickness measured in mm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cognitive assessment - Rey Auditory Verbal Learning Test (RAVLT)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in RAVLT score</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive Assessment - Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in DSST score</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional Assessment - Amsterdam Instrumental Activities of Daily Living (A-IADL)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in A-IADL score</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive Assessment - Mini Mental State Examination (MMSE)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in MMSE score</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Assessment - Clinical Dementia Rating - Sum of Boxes (CDR-SB)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in CDR-SB score</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Early Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 265 mg tablets once daily for two weeks and twice daily thereafter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ-801</intervention_name>
    <description>ALZ-801 265 mg twice daily (BID)</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age between 50 and 80 years, inclusive.&#xD;
&#xD;
          2. Early Alzheimer's Disease (AD): a diagnosis of Probable AD Dementia or Mild Cognitive&#xD;
             Impairment (MCI) due to AD in accordance with the National Institute on&#xD;
             Aging-Alzheimer's Association (NIA-AA) Working Group Criteria [Albert et al, 2011;&#xD;
             McKhann et al, 2011].&#xD;
&#xD;
          3. One of the following apolipoprotein E (APOE) genotypes - either APOE4/4 (homozygous)&#xD;
             or APOE3/4 (heterozygous).&#xD;
&#xD;
          4. MMSE score 22 to 30 inclusive; Clinical Dementia Rating (CDR)-Global Score of 0.5 or&#xD;
             1.0, and CDR Memory Box Score of ≥ 0.5.&#xD;
&#xD;
          5. Documented confirmation of AD diagnosis by either positive amyloid positron emission&#xD;
             tomography (PET) or positive CSF AD signature. Subjects without documented positive AD&#xD;
             biomarker status must have a positive CSF biomarker result from a sample provided at&#xD;
             screening.&#xD;
&#xD;
          6. Stable doses of acetylcholinesterase for the duration of the study are allowed.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Brain MRI at screening indicative of significant abnormality&#xD;
&#xD;
          2. Diagnosis of neurodegenerative disorder other than AD&#xD;
&#xD;
          3. Current diagnosis of Major Depressive Disorder (MDD)&#xD;
&#xD;
          4. Concomitant treatment with memantine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Hey, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alzheon Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anne's University Hospital</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestra Clinics</name>
      <address>
        <city>Rychnov Nad Kněžnou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

